Olema Pharmaceuticals(US:OLMA) Seeking Alpha·2026-02-13 21:47Company Overview - Olema is focused on transforming the standard of care for patients with ER-positive, HER2-negative breast cancer, which represents a significant unmet medical need [2] - Breast cancer is the most common cancer diagnosis in women globally and the second leading cause of cancer death, with ER-positive, HER2-negative breast cancer accounting for 70% of cases [2] Lead Program - The lead program of Olema is palazestrant, a complete estrogen receptor antagonist, which serves as the backbone therapy for ER-positive HER2-negative breast cancer [3] - Endocrine therapy is administered in every line of treatment until chemotherapy is necessary, with the goal of delaying chemotherapy as long as possible [3] Clinical Trials - Palazestrant is currently in two Phase III trials: one as a monotherapy in the second and third-line setting, with results expected in the fall, and another in combination with ribociclib in the first-line setting [4]